Tempest Therapeutics Exercises Option to License Senlang’s CD7-Targeted Lentiviral In Vivo CAR-T Platform Following Initial Phase 1 Results with Lead BCMA/GPRC5D Candidate
Press Release: Agenus Reports Third Quarter 2026 Results, Highlighted by First Marketing Authorizations for Bot+bal and Global Investigator Support for Phase 3 Robbin Study